High-Purity Compound S-217622 Synthesis and Purification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The existing method for preparing the compound S-217622 has a low yield and impurity issues, leading to a product with only 86% purity, which is not suitable for industrial production and may affect the efficacy and safety of the drug due to similar impurities that are difficult to purify.
Innovation Solution
A composition comprising a compound of formula (I) with a HPLC purity of ≥90% is developed, along with a method for preparing a physiologically acceptable salt, such as a fumarate salt, to enhance purity and stability, and improve the drug's fluidity and anti-caking properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If the existing method for preparing compound S-217622 is used, then the synthesis process is simple, but the yield is low (25%) and the purity is insufficient (86%)
Solution Approach 1:
The patent applies parameter changes by optimizing reaction conditions including temperature control (0°C to room temperature), solvent selection (THF), base addition (LHMDS), and reaction time to achieve both high yield and high purity in the synthesis of compound S-217622
Solution Approach 2:
The patent uses an intermediate purification step where the crude product is isolated and purified through recrystallization or chromatography to remove impurities, thereby achieving the required ≥90% purity while maintaining acceptable yield
2Reliability
If the existing method is used, then the synthesis procedure is established, but impurities are generated that are difficult to purify and may affect drug efficacy and safety
Solution Approach 1:
The patent converts the harmful impurities into removable byproducts by optimizing the reaction to generate impurities with different physical properties (solubility, polarity) that can be effectively separated through purification techniques, thereby ensuring drug safety and efficacy
Solution Approach 2:
The patent employs extraction and purification techniques to remove harmful impurities from the reaction mixture, isolating the pure compound S-217622 and eliminating substances that could compromise drug efficacy or safety
3Manufacturing precision
If the existing method is used, then the synthesis route is known, but the product cannot meet pharmaceutical requirements due to insufficient purity
Solution Approach 1:
The patent incorporates preliminary purification actions in the synthesis protocol, including in-situ precipitation, filtration, and recrystallization steps that prepare the product for pharmaceutical standards while maintaining scalability for industrial production
Data Source
AI summary
The present disclosure provides a composition comprising a compound of formula (I) or a physiologically acceptable salt thereof, in which the compound of formula (I) or a physiologically acceptable salt thereof has a HPLC purity of ≥90%;wherein R1, R2, X and n are as defined herein. The present disclosure further provides use of the composition according to the present disclosure for preparing and/or purifying a composition comprising a salt of the compound of formula (I), and a method for treating a disease caused by a Coronavirus which comprises administering the composition of the present disclosure to a subject. The composition of the present disclosure comprises the compound of formula (I) with high purity, and has good fluidity and anti-caking property; moreover, the claimed composition comprising the compound of formula (I)) with high purity is more suitable for preparing a composition comprising a salt of the compound of formula (I) with higher purity.